Hopes for access to the drug were immediately dashed by cost-effectiveness watchdog NICE – the ultimate arbiter ... The MHRA's interim head of healthcare quality and access, Julian Breach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback